Skip to main content

Advertisement

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Fig. 3

Change from baseline in composite endpoint scores by MDA response status across studies, a PASDAS, b DAPSA, c CPDAI, d DAS28-3 (CRP). For complete data, see Additional file 2: Table S2. MDA response was defined as five of the following seven criteria being met: TJC ≤1, SJC ≤1, Psoriasis Area and Severity Index score ≤1 or psoriasis BSA ≤3%, patient arthritis pain (VAS) ≤15 mm, patient’s global assessment of arthritis (VAS) ≤20 mm, HAQ-DI ≤0.5, tender entheseal points (using LEI) ≤1. Abbreviations: BID twice daily, BSA body surface area, CPDAI Composite Psoriatic Disease Activity Index, DAPSA Disease Activity Index for Psoriatic Arthritis, DAS28–3(CRP) 3-component Disease Activity Score using 28 joints with C-reactive protein, FAS full analysis set, HAQ-DI Health Assessment Questionnaire-Disability Index, LEI Leeds Enthesitis Index, MDA minimal disease activity, OPAL Oral Psoriatic Arthritis triaL, PASDAS Psoriatic Arthritis Disease Activity Score, Q2W once every 2 weeks, SC subcutaneous, SJC swollen joint count, TJC tender joint count, VAS visual analog scale

Back to article page